Sugi Predict

Sugi Predict / Targets / SLC16A3

SLC16A3

Monocarboxylate transporter 4 · O15427 · SLC16A3 on Sugi Atlas →

30,570 patent compounds predicted against SLC16A3, 18,755 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL929883 SCHEMBL929883 0.74 20/20
SCHEMBL927777 SCHEMBL927777 0.64 20/20
SCHEMBL928309 SCHEMBL928309 0.76 19/20
SCHEMBL927411 SCHEMBL927411 0.80 18/20
SCHEMBL926958 SCHEMBL926958 0.78 18/20
SCHEMBL928596 SCHEMBL928596 0.76 18/20
SCHEMBL928717 SCHEMBL928717 0.87 17/20
SCHEMBL927983 SCHEMBL927983 0.83 16/20
Bindarit Bindarit (SCHEMBL187885) 1.00 15/20
Bindarit Bindarit (SCHEMBL371677) 0.98 15/20
SCHEMBL928508 SCHEMBL928508 0.87 14/20
SCHEMBL927364 SCHEMBL927364 0.81 12/20
SCHEMBL927862 SCHEMBL927862 0.78 12/20
Clobuzarit Clobuzarit (SCHEMBL187456) 0.62 10/20
SCHEMBL530537 SCHEMBL530537 0.58 10/20
SCHEMBL729909 SCHEMBL729909 0.58 10/20
SCHEMBL328455 SCHEMBL328455 0.57 10/20
SCHEMBL690676 SCHEMBL690676 0.55 10/20
SCHEMBL472982 SCHEMBL472982 0.54 10/20
SCHEMBL321495 SCHEMBL321495 0.53 10/20

Clinical trials — most relevant to SLC16A3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Genetic Basis for Variation in the Renal Elimination of Metformin PHASE4COMPLETED
Dapagliflozin Effect on Erythropoiesis and Physical Fitness PHASE4WITHDRAWN
Chronic Versus Acute Dosing of Sodium Citrate for Swimming 200m PHASE3COMPLETED
Hyperpolarized 13C Pyruvate MRI Scan in Predicting Tumor Aggressiveness in Patients With Renal Tumors PHASE2ACTIVE_NOT_RECRUITING
A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation. PHASE2RECRUITING
Effect of Genetic Variants in MATE1 and OCT3 on the Pharmacodynamics of Metformin in African Americans PHASE1COMPLETED
Inter- and Intra-individual Variations in Metformin Pharmacokinetics - The Importance of Genes and Drug Interactions PHASE1COMPLETED
Effect of, OAT3, on the Renal Secretion of Cefotaxime PHASE1COMPLETED
Evaluate the Effect of Vimseltinib on Organic Cation Transporter 2 (OCT2) PHASE1COMPLETED
Effect of Omeprazole on Metformin PHASE1COMPLETED
Pharmacokinetic Drug-Drug Interaction Study to Identify Biomarkers of Kidney Transporters EARLY_PHASE1COMPLETED
Metformin Gastrointestinal Intolerance: Measurement of Mitochondrial Complex I EARLY_PHASE1COMPLETED
Gadoxetate Sodium Enhanced MRI as a Biomarker for Aggressive Prostate Cancer EARLY_PHASE1UNKNOWN
Sodium Lactate Infusion in GLUT1DS Patients EARLY_PHASE1COMPLETED
Hyperlactacidemia in Major Abdominal Surgery and Monocarboxylate Receptors nanUNKNOWN
Erythrocyte Transport of Lactate During Exercise (TELE Project) nanRECRUITING
Register for Patients With Thyroid Hormone Resistance. nanRECRUITING
Impact of Polymorphisms of OAT1, OAT3, and OCT2 on Transportation of Potential Nephrotoxic Drugs nanCOMPLETED
Impact of Genetics on Metformin Pharmacokinetics nanCOMPLETED
Natural History Study of SLC25A46 Mutation-related Mitochondriopathy nanCOMPLETED
Oxalate and Citrate in Humans - Response to Citrate nanRECRUITING
A Proof-of-concept Study Evaluating the Microbiota-gut-brain Axis nanRECRUITING
Glutamate Supplementation in Young Men nanCOMPLETED
Variations in the DIO2 and MCT10 Genes and Effect of Triiodothyronine Treatment nanCOMPLETED
Triheptanoin (UX007) to Treat Citrate Transporter Deficiency nanNO_LONGER_AVAILABLE
Fatty Acid Metabolism and Insulin Sensitivity: the Role of Endurance Exercise nanCOMPLETED
Harmonic Ratio in Patients With GLUT1 Deficiency Syndrome nanACTIVE_NOT_RECRUITING
Influence of OCTN2 Variants on Carnitine Status and Plasma Triglycerides nanCOMPLETED
Clinical and Laboratory Study of Methylmalonic Acidemia nanRECRUITING
Does a Ketogenic Dietary Supplement Reduce Alcohol Withdrawal Symptoms in Humans? nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a SLC16A3 binder may also engage these)

ProteinNameSimilarity
P57787 — 1.000 P57787 →
O35910 — 0.995 O35910 →
P57788 — 0.975 P57788 →
SLC16A7 Monocarboxylate transporter 2 0.958 landscape →
SPNS2 Sphingosine-1-phosphate transporter SPNS2 0.937 landscape →
P53986 — 0.936 P53986 →
Q03064 — 0.934 Q03064 →
Q58CV5 — 0.933 Q58CV5 →
Q91VM4 — 0.933 Q91VM4 →
P53987 — 0.931 P53987 →
Q8BRU6 — 0.928 Q8BRU6 →
P53988 — 0.927 P53988 →
SLC16A1 Monocarboxylate transporter 1 0.926 landscape →
Q27963 — 0.926 Q27963 →
Q504N2 — 0.925 Q504N2 →
Q8TED4 — 0.925 Q8TED4 →
Q3MHW6 — 0.925 Q3MHW6 →
Q8IZD6 — 0.922 Q8IZD6 →
Q8VCV9 — 0.922 Q8VCV9 →
Q9WU81 — 0.921 Q9WU81 →
F1NCD6 — 0.919 F1NCD6 →
SLC18A2 Synaptic vesicular amine transporter 0.919 landscape →
Q7SY29 — 0.915 Q7SY29 →
Q01827 — 0.914 Q01827 →
O70461 — 0.912 O70461 →
Q2M3R5 — 0.912 Q2M3R5 →
SLC18A1 Chromaffin granule amine transporter 0.911 landscape →
Q3T9X0 — 0.909 Q3T9X0 →
Q01818 — 0.908 Q01818 →
Q1JQC1 — 0.908 Q1JQC1 →